Industry Research Reports

Home > Reports > Service & Software > Global AI Drug Repurposing Platform Market Outlook, In‑Depth Analysis & Forecast to 2032

Global AI Drug Repurposing Platform Market Outlook, In‑Depth Analysis & Forecast to 2032

Industry: Service & Software

Published Date: 2026-07-17

Pages: 118 Pages

Report ld: 6977599

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

AI Drug Repurposing Platform Market Size(US$)

CAGR 2026-2032

24.5%

Market Size,2032

USD 6,331

Million

Market Snapshot

Market Size in 2026 (Value)

US$ 1,700 million

Market Forecast in 2032(Value)

US$ 6,331 million

CAGR

24.5%

Years Considered

2021-2032

Base Year

2026

Forecast Period

2026-2032

Source: Secondary research, interviews with experts, and QYResearch analysis

The global AI Drug Repurposing Platform market is projected to grow from US$ 1300 million in 2025 to US$ 6331 million by 2032, at a CAGR of 24.5% (2026-2032), driven by critical product segments and diverse end‑use applications.

An AI drug repurposing platform is a computational analytics system for approved drugs, clinical-stage assets and shelved compounds. It integrates biomedical knowledge graphs, omics data, clinical trials, real-world data, literature and patent information, and uses machine learning, network medicine, causal inference and large language models to identify new drug-disease links, indication expansion opportunities, combination-therapy leads and translational evidence. It mainly serves pharmaceutical companies, biotechs, research institutes and foundations in pipeline reassessment, rare-disease development and asset rescue, with a blended gross margin of about 65%.

Demand is mainly driven by pharmaceutical cost reduction, redevelopment of existing assets under patent-cliff pressure, rare-disease and niche-indication development, and public-health response scenarios. Compared with de novo drug discovery, repurposing platforms re-rank drug-disease relationships on the basis of existing safety, pharmacokinetic and clinical experience, making them easier to move into proof-of-concept validation, indication expansion and out-licensing discussions.

The supply side is moving from simple literature mining or similarity search toward integrated knowledge graphs, multi-omics, real-world data, clinical-trial data and explainable models. Buyers evaluate not only algorithmic hit rates, but also data coverage, evidence traceability, private-data integration, API or private deployment, security compliance and wet-lab validation capability. Suppliers that combine platform software, expert services and experimental validation loops are better positioned for long-term partnerships.

Regional demand is led by large pharmaceutical companies, biotechs and research foundations in North America and Europe, while Asia-Pacific is benefiting from local innovative-drug pipelines and rising investment in AI-enabled pharma. Key risks include public-data bias, real-world-data compliance, verifiability of predictions and complex commercial rights around candidate drugs, but the return on investment remains attractive for customers with shelved assets, indication-expansion needs and rare-disease programs.

Report Includes:

This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global AI Drug Repurposing Platform market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.

By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.

Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.

Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand.

MARKET SEGMENTATION

By Company

BenevolentAI
Healx
Insilico Medicine
Recursion
Lantern Pharma
SOM Biotech
Standigm
Pharos iBio
Aitia
Causaly

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

Target and Mechanism Mining
Drug–Disease Matching
Indication Expansion
Combination Therapy Prediction
Evidence Ranking and Validation
Safety and Translational Assessment

Segment by Application

Rare Disease Repurposing
Oncology Indication Expansion
Infectious Disease Response
CNS and Neurology Research
Immunology and Inflammation Research
Asset Rescue and Pipeline Optimization

Segment by Category

Biomedical Knowledge Graphs
Multi-Omics Data
Clinical and Real-World Data
Literature and Patent Data
Chemical and Target Interaction Data
Integrated Multimodal Data

Segment by Division

Knowledge Graph Reasoning
Machine Learning Prediction
Network Medicine Analysis
Causal Inference Modeling
Generative and Language Models
Hybrid Expert-in-the-Loop Models

biaoTi CHAPTER OUTLINE

Chapter 1: Defines the AI Drug Repurposing Platform study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential

Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts

Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves

Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks

Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application

Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers

Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers

Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas

Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges

Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles

Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments

Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels

Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies

Chapter 14: Actionable conclusions and strategic recommendations.

WHY THIS REPORT

Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:

Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).

Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.

Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).

Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).

Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Study Coverage

1.1 Introduction to AI Drug Repurposing Platform: Definition, Properties, and Key Attributes

1.2 Market Segmentation by Type

1.2.1 Global AI Drug Repurposing Platform Market Size by Type, 2021 vs 2025 vs 2032

1.2.2 Target and Mechanism Mining

1.2.3 Drug–Disease Matching

1.2.4 Indication Expansion

1.2.5 Combination Therapy Prediction

1.2.6 Evidence Ranking and Validation

1.2.7 Safety and Translational Assessment

1.3 Market Segmentation by Data Foundation

1.3.1 Global AI Drug Repurposing Platform Market Size by Data Foundation, 2021 vs 2025 vs 2032

1.3.2 Biomedical Knowledge Graphs

1.3.3 Multi-Omics Data

1.3.4 Clinical and Real-World Data

1.3.5 Literature and Patent Data

1.3.6 Chemical and Target Interaction Data

1.3.7 Integrated Multimodal Data

1.4 Market Segmentation by Algorithmic Method

1.4.1 Global AI Drug Repurposing Platform Market Size by Algorithmic Method, 2021 vs 2025 vs 2032

1.4.2 Knowledge Graph Reasoning

1.4.3 Machine Learning Prediction

1.4.4 Network Medicine Analysis

1.4.5 Causal Inference Modeling

1.4.6 Generative and Language Models

1.4.7 Hybrid Expert-in-the-Loop Models

1.5 Market Segmentation by Delivery Mode

1.5.1 Global AI Drug Repurposing Platform Market Size by Delivery Mode, 2021 vs 2025 vs 2032

1.5.2 SaaS Platform

1.5.3 Private Deployment

1.5.4 API and Data Service

1.5.5 Project-Based Collaboration

1.5.6 Platform with Wet-Lab Validation

1.6 Market Segmentation by Application

1.6.1 Global AI Drug Repurposing Platform Market Size by Application, 2021 vs 2025 vs 2032

1.6.2 Rare Disease Repurposing

1.6.3 Oncology Indication Expansion

1.6.4 Infectious Disease Response

1.6.5 CNS and Neurology Research

1.6.6 Immunology and Inflammation Research

1.6.7 Asset Rescue and Pipeline Optimization

1.7 Assumptions and Limitations

1.8 Study Objectives

1.9 Years Considered

2 Executive Summary

2.1 Global AI Drug Repurposing Platform Revenue Estimates and Forecasts (2021-2032)

2.2 Global AI Drug Repurposing Platform Revenue by Region

2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032

2.2.2 Historical and Forecasted Revenue by Region (2021-2032)

2.2.3 Global Revenue-Based Market Share by Region (2021-2032)

2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends

3 Competitive Landscape

3.1 Global AI Drug Repurposing Platform Players’ Revenue Rankings and Profitability

3.1.1 Global Revenue (Value) by Players (2021-2026)

3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025)

3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)

3.1.4 Gross Margin by Top Players (2021 vs 2025)

3.2 Global AI Drug Repurposing Platform Companies Headquarters and Service Footprint

3.3 Key Player Market Share by Product Type

3.3.1 Target and Mechanism Mining: Market Share by Key Players

3.3.2 Drug–Disease Matching: Market Share by Key Players

3.3.3 Indication Expansion: Market Share by Key Players

3.3.4 Combination Therapy Prediction: Market Share by Key Players

3.3.5 Evidence Ranking and Validation: Market Share by Key Players

3.3.6 Safety and Translational Assessment: Market Share by Key Players

3.4 Global AI Drug Repurposing Platform Market Concentration and Dynamics

3.4.1 Global Market Concentration

3.4.2 Market Entry and Exit Analysis

3.4.3 Strategic Moves: M&A, Expansion, R&D Investment

4 Product Segmentation

4.1 Global AI Drug Repurposing Platform Market by Type

4.1.1 Global Revenue by Type (2021-2032)

4.1.2 Global Revenue-Based Market Share by Type (2021-2032)

4.2 Global AI Drug Repurposing Platform Market by Data Foundation

4.2.1 Global Revenue by Data Foundation (2021-2032)

4.2.2 Global Revenue-Based Market Share by Data Foundation (2021-2032)

4.3 Global AI Drug Repurposing Platform Market by Algorithmic Method

4.3.1 Global Revenue by Algorithmic Method (2021-2032)

4.3.2 Global Revenue-Based Market Share by Algorithmic Method (2021-2032)

4.4 Global AI Drug Repurposing Platform Market by Delivery Mode

4.4.1 Global Revenue by Delivery Mode (2021-2032)

4.4.2 Global Revenue-Based Market Share by Delivery Mode (2021-2032)

4.5 Key Product Attributes and Differentiation

4.6 Subtype Dynamics: Growth Leaders, Profitability and Risk

4.6.1 High-Growth Niches and Adoption Drivers

4.6.2 Profitability Hotspots and Cost Drivers

4.6.3 Substitution Threats

5 Downstream Applications and Customers

5.1 Global AI Drug Repurposing Platform Revenue by Application

5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032)

5.1.2 Revenue-Based Market Share by Application (2021-2032)

5.1.3 High-Growth Application Identification

5.1.4 Emerging Application Case Studies

5.2 Downstream Customer Analysis

5.2.1 Top Customers by Region

5.2.2 Top Customers by Application

6 North America

6.1 North America Market Size (2021-2032)

6.2 North America Key Players’ Revenue in 2025

6.3 North America AI Drug Repurposing Platform Market Size by Application (2021-2032)

6.4 North America Growth Accelerators and Market Barriers

6.5 North America AI Drug Repurposing Platform Market Size by Country

6.5.1 North America Revenue Trends by Country

6.5.2 US

6.5.3 Canada

6.5.4 Mexico

7 Europe

7.1 Europe Market Size (2021-2032)

7.2 Europe Key Players’ Revenue in 2025

7.3 Europe AI Drug Repurposing Platform Market Size by Application (2021-2032)

7.4 Europe Growth Accelerators and Market Barriers

7.5 Europe AI Drug Repurposing Platform Market Size by Country

7.5.1 Europe Revenue Trends by Country

7.5.2 Germany

7.5.3 France

7.5.4 U.K.

7.5.5 Italy

7.5.6 Russia

8 Asia-Pacific

8.1 Asia-Pacific Market Size (2021-2032)

8.2 Asia-Pacific Key Players’ Revenue in 2025

8.3 Asia-Pacific AI Drug Repurposing Platform Market Size by Application (2021-2032)

8.4 Asia-Pacific Growth Accelerators and Market Barriers

8.5 Asia-Pacific AI Drug Repurposing Platform Market Size by Region

8.5.1 Asia-Pacific Revenue Trends by Region

8.6 China

8.7 Japan

8.8 South Korea

8.9 Australia

8.10 India

8.11 Southeast Asia

8.11.1 Indonesia

8.11.2 Vietnam

8.11.3 Malaysia

8.11.4 Philippines

8.11.5 Singapore

9 Central and South America

9.1 Central and South America Market Size (2021-2032)

9.2 Central and South America Key Players’ Revenue in 2025

9.3 Central and South America AI Drug Repurposing Platform Market Size by Application (2021-2032)

9.4 Central and South America Investment Opportunities and Key Challenges

9.5 Central and South America AI Drug Repurposing Platform Market Size by Country

9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)

9.5.2 Brazil

9.5.3 Argentina

10 Middle East and Africa

10.1 Middle East and Africa Market Size (2021-2032)

10.2 Middle East and Africa Key Players’ Revenue in 2025

10.3 Middle East and Africa AI Drug Repurposing Platform Market Size by Application (2021-2032)

10.4 Middle East and Africa Investment Opportunities and Key Challenges

10.5 Middle East and Africa AI Drug Repurposing Platform Market Size by Country

10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)

10.5.2 GCC Countries

10.5.3 Israel

10.5.4 Egypt

10.5.5 South Africa

11 Corporate Profile

11.1 BenevolentAI

11.1.1 BenevolentAI Corporation Information

11.1.2 BenevolentAI Business Overview

11.1.3 BenevolentAI AI Drug Repurposing Platform Product Features and Attributes

11.1.4 BenevolentAI AI Drug Repurposing Platform Revenue and Gross Margin (2021-2026)

11.1.5 BenevolentAI AI Drug Repurposing Platform Revenue by Product in 2025

11.1.6 BenevolentAI AI Drug Repurposing Platform Revenue by Application in 2025

11.1.7 BenevolentAI AI Drug Repurposing Platform Revenue by Geographic Area in 2025

11.1.8 BenevolentAI AI Drug Repurposing Platform SWOT Analysis

11.1.9 BenevolentAI Recent Developments

11.2 Healx

11.2.1 Healx Corporation Information

11.2.2 Healx Business Overview

11.2.3 Healx AI Drug Repurposing Platform Product Features and Attributes

11.2.4 Healx AI Drug Repurposing Platform Revenue and Gross Margin (2021-2026)

11.2.5 Healx AI Drug Repurposing Platform Revenue by Product in 2025

11.2.6 Healx AI Drug Repurposing Platform Revenue by Application in 2025

11.2.7 Healx AI Drug Repurposing Platform Revenue by Geographic Area in 2025

11.2.8 Healx AI Drug Repurposing Platform SWOT Analysis

11.2.9 Healx Recent Developments

11.3 Insilico Medicine

11.3.1 Insilico Medicine Corporation Information

11.3.2 Insilico Medicine Business Overview

11.3.3 Insilico Medicine AI Drug Repurposing Platform Product Features and Attributes

11.3.4 Insilico Medicine AI Drug Repurposing Platform Revenue and Gross Margin (2021-2026)

11.3.5 Insilico Medicine AI Drug Repurposing Platform Revenue by Product in 2025

11.3.6 Insilico Medicine AI Drug Repurposing Platform Revenue by Application in 2025

11.3.7 Insilico Medicine AI Drug Repurposing Platform Revenue by Geographic Area in 2025

11.3.8 Insilico Medicine AI Drug Repurposing Platform SWOT Analysis

11.3.9 Insilico Medicine Recent Developments

11.4 Recursion

11.4.1 Recursion Corporation Information

11.4.2 Recursion Business Overview

11.4.3 Recursion AI Drug Repurposing Platform Product Features and Attributes

11.4.4 Recursion AI Drug Repurposing Platform Revenue and Gross Margin (2021-2026)

11.4.5 Recursion AI Drug Repurposing Platform Revenue by Product in 2025

11.4.6 Recursion AI Drug Repurposing Platform Revenue by Application in 2025

11.4.7 Recursion AI Drug Repurposing Platform Revenue by Geographic Area in 2025

11.4.8 Recursion AI Drug Repurposing Platform SWOT Analysis

11.4.9 Recursion Recent Developments

11.5 Lantern Pharma

11.5.1 Lantern Pharma Corporation Information

11.5.2 Lantern Pharma Business Overview

11.5.3 Lantern Pharma AI Drug Repurposing Platform Product Features and Attributes

11.5.4 Lantern Pharma AI Drug Repurposing Platform Revenue and Gross Margin (2021-2026)

11.5.5 Lantern Pharma AI Drug Repurposing Platform Revenue by Product in 2025

11.5.6 Lantern Pharma AI Drug Repurposing Platform Revenue by Application in 2025

11.5.7 Lantern Pharma AI Drug Repurposing Platform Revenue by Geographic Area in 2025

11.5.8 Lantern Pharma AI Drug Repurposing Platform SWOT Analysis

11.5.9 Lantern Pharma Recent Developments

11.6 SOM Biotech

11.6.1 SOM Biotech Corporation Information

11.6.2 SOM Biotech Business Overview

11.6.3 SOM Biotech AI Drug Repurposing Platform Product Features and Attributes

11.6.4 SOM Biotech AI Drug Repurposing Platform Revenue and Gross Margin (2021-2026)

11.6.5 SOM Biotech Recent Developments

11.7 Standigm

11.7.1 Standigm Corporation Information

11.7.2 Standigm Business Overview

11.7.3 Standigm AI Drug Repurposing Platform Product Features and Attributes

11.7.4 Standigm AI Drug Repurposing Platform Revenue and Gross Margin (2021-2026)

11.7.5 Standigm Recent Developments

11.8 Pharos iBio

11.8.1 Pharos iBio Corporation Information

11.8.2 Pharos iBio Business Overview

11.8.3 Pharos iBio AI Drug Repurposing Platform Product Features and Attributes

11.8.4 Pharos iBio AI Drug Repurposing Platform Revenue and Gross Margin (2021-2026)

11.8.5 Pharos iBio Recent Developments

11.9 Aitia

11.9.1 Aitia Corporation Information

11.9.2 Aitia Business Overview

11.9.3 Aitia AI Drug Repurposing Platform Product Features and Attributes

11.9.4 Aitia AI Drug Repurposing Platform Revenue and Gross Margin (2021-2026)

11.9.5 Aitia Recent Developments

11.10 Causaly

11.10.1 Causaly Corporation Information

11.10.2 Causaly Business Overview

11.10.3 Causaly AI Drug Repurposing Platform Product Features and Attributes

11.10.4 Causaly AI Drug Repurposing Platform Revenue and Gross Margin (2021-2026)

11.10.5 Company Ten Recent Developments

12 AI Drug Repurposing Platform Value Chain and Ecosystem Analysis

12.1 AI Drug Repurposing Platform Value Chain (Ecosystem Structure)

12.2 Upstream Analysis

12.2.1 Key Technologies, Platforms and Infrastructure

12.3 Midstream Analysis

12.4 Downstream Sales Model and Distribution Networks

12.4.1 Sales Channels

12.4.2 Distributors

13 AI Drug Repurposing Platform Market Dynamics

13.1 Industry Trends and Evolution

13.2 Market Growth Drivers and Emerging Opportunities

13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global AI Drug Repurposing Platform Study

15 Appendix

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.1.1 Research Programs/Design

15.1.1.2 Market Size Estimation

15.1.1.3 Market Breakdown and Data Triangulation

15.1.2 Data Source

15.1.2.1 Secondary Sources

15.1.2.2 Primary Sources

15.2 Author Details

TABLE OF FIGURES

List of Tables

Table 1. Global AI Drug Repurposing Platform Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)

Table 2. Global AI Drug Repurposing Platform Market Size Growth Rate by Data Foundation, 2021 vs 2025 vs 2032 (US$ Million)

Table 3. Global AI Drug Repurposing Platform Market Size Growth Rate by Algorithmic Method, 2021 vs 2025 vs 2032 (US$ Million)

Table 4. Global AI Drug Repurposing Platform Market Size Growth Rate by Delivery Mode, 2021 vs 2025 vs 2032 (US$ Million)

Table 5. Global AI Drug Repurposing Platform Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)

Table 6. Global AI Drug Repurposing Platform Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)

Table 7. Global AI Drug Repurposing Platform Revenue by Region (US$ Million), 2021-2026

Table 8. Global AI Drug Repurposing Platform Revenue by Region (US$ Million), 2027-2032

Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)

Table 10. Global AI Drug Repurposing Platform Revenue by Players (US$ Million), 2021-2026

Table 11. Global AI Drug Repurposing Platform Revenue-Based Market Share by Players (2021-2026)

Table 12. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)

Table 13. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on AI Drug Repurposing Platform Revenue, 2025

Table 14. Global AI Drug Repurposing Platform Average Gross Margin (%) by Player (2021 vs 2025)

Table 15. Global AI Drug Repurposing Platform Companies Headquarters

Table 16. Global AI Drug Repurposing Platform Market Concentration Ratio (CR5)

Table 17. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis

Table 18. Key Mergers & Acquisitions, Expansion Plans, R&D Investment

Table 19. Global AI Drug Repurposing Platform Revenue by Type (US$ Million), 2021-2026

Table 20. Global AI Drug Repurposing Platform Revenue by Type (US$ Million), 2027-2032

Table 21. Global AI Drug Repurposing Platform Revenue by Data Foundation (US$ Million), 2021-2026

Table 22. Global AI Drug Repurposing Platform Revenue by Data Foundation (US$ Million), 2027-2032

Table 23. Global AI Drug Repurposing Platform Revenue by Algorithmic Method (US$ Million), 2021-2026

Table 24. Global AI Drug Repurposing Platform Revenue by Algorithmic Method (US$ Million), 2027-2032

Table 25. Global AI Drug Repurposing Platform Revenue by Delivery Mode (US$ Million), 2021-2026

Table 26. Global AI Drug Repurposing Platform Revenue by Delivery Mode (US$ Million), 2027-2032

Table 27. Key Product Attributes and Differentiation

Table 28. Global AI Drug Repurposing Platform Revenue by Application (US$ Million), 2021-2026

Table 29. Global AI Drug Repurposing Platform Revenue by Application (US$ Million), 2027-2032

Table 30. AI Drug Repurposing Platform High-Growth Sectors Demand CAGR (2026-2032)

Table 31. Top Customers by Region

Table 32. Top Customers by Application

Table 33. North America AI Drug Repurposing Platform Growth Accelerators and Market Barriers

Table 34. North America AI Drug Repurposing Platform Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)

Table 35. Europe AI Drug Repurposing Platform Growth Accelerators and Market Barriers

Table 36. Europe AI Drug Repurposing Platform Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 37. Asia-Pacific AI Drug Repurposing Platform Growth Accelerators and Market Barriers

Table 38. Asia-Pacific AI Drug Repurposing Platform Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)

Table 39. Central and South America AI Drug Repurposing Platform Investment Opportunities and Key Challenges

Table 40. Central and South America AI Drug Repurposing Platform Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)

Table 41. Middle East and Africa AI Drug Repurposing Platform Investment Opportunities and Key Challenges

Table 42. Middle East and Africa AI Drug Repurposing Platform Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)

Table 43. BenevolentAI Corporation Information

Table 44. BenevolentAI Description and Major Businesses

Table 45. BenevolentAI Product Features and Attributes

Table 46. BenevolentAI Revenue (US$ Million) and Gross Margin (2021-2026)

Table 47. BenevolentAI Revenue Proportion by Product in 2025

Table 48. BenevolentAI Revenue Proportion by Application in 2025

Table 49. BenevolentAI Revenue Proportion by Geographic Area in 2025

Table 50. BenevolentAI AI Drug Repurposing Platform SWOT Analysis

Table 51. BenevolentAI Recent Developments

Table 52. Healx Corporation Information

Table 53. Healx Description and Major Businesses

Table 54. Healx Product Features and Attributes

Table 55. Healx Revenue (US$ Million) and Gross Margin (2021-2026)

Table 56. Healx Revenue Proportion by Product in 2025

Table 57. Healx Revenue Proportion by Application in 2025

Table 58. Healx Revenue Proportion by Geographic Area in 2025

Table 59. Healx AI Drug Repurposing Platform SWOT Analysis

Table 60. Healx Recent Developments

Table 61. Insilico Medicine Corporation Information

Table 62. Insilico Medicine Description and Major Businesses

Table 63. Insilico Medicine Product Features and Attributes

Table 64. Insilico Medicine Revenue (US$ Million) and Gross Margin (2021-2026)

Table 65. Insilico Medicine Revenue Proportion by Product in 2025

Table 66. Insilico Medicine Revenue Proportion by Application in 2025

Table 67. Insilico Medicine Revenue Proportion by Geographic Area in 2025

Table 68. Insilico Medicine AI Drug Repurposing Platform SWOT Analysis

Table 69. Insilico Medicine Recent Developments

Table 70. Recursion Corporation Information

Table 71. Recursion Description and Major Businesses

Table 72. Recursion Product Features and Attributes

Table 73. Recursion Revenue (US$ Million) and Gross Margin (2021-2026)

Table 74. Recursion Revenue Proportion by Product in 2025

Table 75. Recursion Revenue Proportion by Application in 2025

Table 76. Recursion Revenue Proportion by Geographic Area in 2025

Table 77. Recursion AI Drug Repurposing Platform SWOT Analysis

Table 78. Recursion Recent Developments

Table 79. Lantern Pharma Corporation Information

Table 80. Lantern Pharma Description and Major Businesses

Table 81. Lantern Pharma Product Features and Attributes

Table 82. Lantern Pharma Revenue (US$ Million) and Gross Margin (2021-2026)

Table 83. Lantern Pharma Revenue Proportion by Product in 2025

Table 84. Lantern Pharma Revenue Proportion by Application in 2025

Table 85. Lantern Pharma Revenue Proportion by Geographic Area in 2025

Table 86. Lantern Pharma AI Drug Repurposing Platform SWOT Analysis

Table 87. Lantern Pharma Recent Developments

Table 88. SOM Biotech Corporation Information

Table 89. SOM Biotech Description and Major Businesses

Table 90. SOM Biotech Product Features and Attributes

Table 91. SOM Biotech Revenue (US$ Million) and Gross Margin (2021-2026)

Table 92. SOM Biotech Recent Developments

Table 93. Standigm Corporation Information

Table 94. Standigm Description and Major Businesses

Table 95. Standigm Product Features and Attributes

Table 96. Standigm Revenue (US$ Million) and Gross Margin (2021-2026)

Table 97. Standigm Recent Developments

Table 98. Pharos iBio Corporation Information

Table 99. Pharos iBio Description and Major Businesses

Table 100. Pharos iBio Product Features and Attributes

Table 101. Pharos iBio Revenue (US$ Million) and Gross Margin (2021-2026)

Table 102. Pharos iBio Recent Developments

Table 103. Aitia Corporation Information

Table 104. Aitia Description and Major Businesses

Table 105. Aitia Product Features and Attributes

Table 106. Aitia Revenue (US$ Million) and Gross Margin (2021-2026)

Table 107. Aitia Recent Developments

Table 108. Causaly Corporation Information

Table 109. Causaly Description and Major Businesses

Table 110. Causaly Product Features and Attributes

Table 111. Causaly Revenue (US$ Million) and Gross Margin (2021-2026)

Table 112. Causaly Recent Developments

Table 113. Technologies, Platforms and Infrastructure

Table 114. Distributors List

Table 115. Market Trends and Market Evolution

Table 116. Market Drivers and Opportunities

Table 117. Market Challenges, Risks, and Restraints

Table 118. Research Programs/Design for This Report

Table 119. Key Data Information from Secondary Sources

Table 120. Key Data Information from Primary Sources

List of Figures

Figure 1. Global AI Drug Repurposing Platform Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)

Figure 2. Target and Mechanism Mining Product Picture

Figure 3. Drug–Disease Matching Product Picture

Figure 4. Indication Expansion Product Picture

Figure 5. Combination Therapy Prediction Product Picture

Figure 6. Evidence Ranking and Validation Product Picture

Figure 7. Safety and Translational Assessment Product Picture

Figure 8. Global AI Drug Repurposing Platform Market Size Growth Rate by Data Foundation, 2021 vs 2025 vs 2032 (US$ Million)

Figure 9. Biomedical Knowledge Graphs Product Picture

Figure 10. Multi-Omics Data Product Picture

Figure 11. Clinical and Real-World Data Product Picture

Figure 12. Literature and Patent Data Product Picture

Figure 13. Chemical and Target Interaction Data Product Picture

Figure 14. Integrated Multimodal Data Product Picture

Figure 15. Global AI Drug Repurposing Platform Market Size Growth Rate by Algorithmic Method, 2021 vs 2025 vs 2032 (US$ Million)

Figure 16. Knowledge Graph Reasoning Product Picture

Figure 17. Machine Learning Prediction Product Picture

Figure 18. Network Medicine Analysis Product Picture

Figure 19. Causal Inference Modeling Product Picture

Figure 20. Generative and Language Models Product Picture

Figure 21. Hybrid Expert-in-the-Loop Models Product Picture

Figure 22. Global AI Drug Repurposing Platform Market Size Growth Rate by Delivery Mode, 2021 vs 2025 vs 2032 (US$ Million)

Figure 23. SaaS Platform Product Picture

Figure 24. Private Deployment Product Picture

Figure 25. API and Data Service Product Picture

Figure 26. Project-Based Collaboration Product Picture

Figure 27. Platform with Wet-Lab Validation Product Picture

Figure 28. Global AI Drug Repurposing Platform Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)

Figure 29. Rare Disease Repurposing

Figure 30. Oncology Indication Expansion

Figure 31. Infectious Disease Response

Figure 32. CNS and Neurology Research

Figure 33. Immunology and Inflammation Research

Figure 34. Asset Rescue and Pipeline Optimization

Figure 35. AI Drug Repurposing Platform Report Years Considered

Figure 36. Global AI Drug Repurposing Platform Revenue, (US$ Million), 2021 vs 2025 vs 2032

Figure 37. Global AI Drug Repurposing Platform Revenue (US$ Million), 2021-2032

Figure 38. Global AI Drug Repurposing Platform Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)

Figure 39. Global AI Drug Repurposing Platform Revenue-Based Market Share by Region (2021-2032)

Figure 40. Global AI Drug Repurposing Platform Revenue-Based Market Share Ranking (2025)

Figure 41. Tier Distribution by Revenue Contribution (2021 vs 2025)

Figure 42. Target and Mechanism Mining Revenue-Based Market Share by Player in 2025

Figure 43. Drug–Disease Matching Revenue-Based Market Share by Player in 2025

Figure 44. Indication Expansion Revenue-Based Market Share by Player in 2025

Figure 45. Combination Therapy Prediction Revenue-Based Market Share by Player in 2025

Figure 46. Evidence Ranking and Validation Revenue-Based Market Share by Player in 2025

Figure 47. Safety and Translational Assessment Revenue-Based Market Share by Player in 2025

Figure 48. Global AI Drug Repurposing Platform Revenue-Based Market Share by Type (2021-2032)

Figure 49. Global AI Drug Repurposing Platform Revenue-Based Market Share by Data Foundation (2021-2032)

Figure 50. Global AI Drug Repurposing Platform Revenue-Based Market Share by Algorithmic Method (2021-2032)

Figure 51. Global AI Drug Repurposing Platform Revenue-Based Market Share by Delivery Mode (2021-2032)

Figure 52. Global AI Drug Repurposing Platform Revenue-Based Market Share by Application (2021-2032)

Figure 53. North America AI Drug Repurposing Platform Revenue YoY (US$ Million), 2021-2032

Figure 54. North America Top 5 Players AI Drug Repurposing Platform Revenue (US$ Million) in 2025

Figure 55. North America AI Drug Repurposing Platform Revenue (US$ Million) by Application (2021-2032)

Figure 56. US AI Drug Repurposing Platform Revenue (US$ Million), 2021-2032

Figure 57. Canada AI Drug Repurposing Platform Revenue (US$ Million), 2021-2032

Figure 58. Mexico AI Drug Repurposing Platform Revenue (US$ Million), 2021-2032

Figure 59. Europe AI Drug Repurposing Platform Revenue YoY (US$ Million), 2021-2032

Figure 60. Europe Top 5 Players AI Drug Repurposing Platform Revenue (US$ Million) in 2025

Figure 61. Europe AI Drug Repurposing Platform Revenue (US$ Million) by Application (2021-2032)

Figure 62. Germany AI Drug Repurposing Platform Revenue (US$ Million), 2021-2032

Figure 63. France AI Drug Repurposing Platform Revenue (US$ Million), 2021-2032

Figure 64. U.K. AI Drug Repurposing Platform Revenue (US$ Million), 2021-2032

Figure 65. Italy AI Drug Repurposing Platform Revenue (US$ Million), 2021-2032

Figure 66. Russia AI Drug Repurposing Platform Revenue (US$ Million), 2021-2032

Figure 67. Asia-Pacific AI Drug Repurposing Platform Revenue YoY (US$ Million), 2021-2032

Figure 68. Asia-Pacific Top 8 Players AI Drug Repurposing Platform Revenue (US$ Million) in 2025

Figure 69. Asia-Pacific AI Drug Repurposing Platform Revenue (US$ Million) by Application (2021-2032)

Figure 70. Indonesia AI Drug Repurposing Platform Revenue (US$ Million), 2021-2032

Figure 71. Japan AI Drug Repurposing Platform Revenue (US$ Million), 2021-2032

Figure 72. South Korea AI Drug Repurposing Platform Revenue (US$ Million), 2021-2032

Figure 73. Australia AI Drug Repurposing Platform Revenue (US$ Million), 2021-2032

Figure 74. India AI Drug Repurposing Platform Revenue (US$ Million), 2021-2032

Figure 75. Indonesia AI Drug Repurposing Platform Revenue (US$ Million), 2021-2032

Figure 76. Vietnam AI Drug Repurposing Platform Revenue (US$ Million), 2021-2032

Figure 77. Malaysia AI Drug Repurposing Platform Revenue (US$ Million), 2021-2032

Figure 78. Philippines AI Drug Repurposing Platform Revenue (US$ Million), 2021-2032

Figure 79. Singapore AI Drug Repurposing Platform Revenue (US$ Million), 2021-2032

Figure 80. Central and South America AI Drug Repurposing Platform Revenue YoY (US$ Million), 2021-2032

Figure 81. Central and South America Top 5 Players AI Drug Repurposing Platform Revenue (US$ Million) in 2025

Figure 82. Central and South America AI Drug Repurposing Platform Revenue (US$ Million) by Application (2021-2032)

Figure 83. Brazil AI Drug Repurposing Platform Revenue (US$ Million), 2021-2032

Figure 84. Argentina AI Drug Repurposing Platform Revenue (US$ Million), 2021-2032

Figure 85. Middle East and Africa AI Drug Repurposing Platform Revenue YoY (US$ Million), 2021-2032

Figure 86. Middle East and Africa Top 5 Players AI Drug Repurposing Platform Revenue (US$ Million) in 2025

Figure 87. Middle East and Africa AI Drug Repurposing Platform Revenue (US$ Million) by Application (2021-2032)

Figure 88. GCC Countries AI Drug Repurposing Platform Revenue (US$ Million), 2021-2032

Figure 89. Israel AI Drug Repurposing Platform Revenue (US$ Million), 2021-2032

Figure 90. Egypt AI Drug Repurposing Platform Revenue (US$ Million), 2021-2032

Figure 91. South Africa AI Drug Repurposing Platform Revenue (US$ Million), 2021-2032

Figure 92. AI Drug Repurposing Platform Value Chain Mapping

Figure 93. Channels of Distribution (Direct Vs Distribution)

Figure 94. Bottom-up and Top-down Approaches for This Report

Figure 95. Data Triangulation

Figure 96. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

What was the global market size of AI Drug Repurposing Platform in 2026? zhanKai

The global market size of AI Drug Repurposing Platform in 2026 was 1700 Million USD.

Which region is expected to have the highest market share? shouQi

Which companies rank high in the global AI Drug Repurposing Platform market? shouQi

What was the global market size of AI Drug Repurposing Platform in 2032? shouQi

What is the annual compound growth rate of the global AI Drug Repurposing Platform market size from 2026 to 2032? shouQi

Related Reports

Global AI Drug Repurposing Platform Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global AI Drug Repurposing Platform market size was US$ 1300 million in 2025 and is forecast to reach a readjusted size of US$ 6331 million by 2032 with a CAGR of 24.5% during the forecast period 2026-2032.
Published Date: 2026-07-17
Pages: 109
USD 4250.00
(Single User License)
AI Drug Repurposing Platform - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for AI Drug Repurposing Platform was estimated to be worth US$ 1300 million in 2025 and is projected to reach US$ 6331 million, growing at a CAGR of 24.5% from 2026 to 2032.
Published Date: 2026-07-17
Pages: 107
USD 3950.00
(Single User License)
Global AI Drug Repurposing Platform Market Research Report 2026
The global AI Drug Repurposing Platform market was valued at US$ 1300 million in 2025 and is anticipated to reach US$ 6331 million by 2032, at a CAGR of 24.5% from 2026 to 2032.
Published Date: 2026-07-17
Pages: 106
USD 2900.00
(Single User License)

Global AI Drug Repurposing Platform Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global AI Drug Repurposing Platform market size was US$ 1300 million in 2025 and is forecast to reach a readjusted size of US$ 6331 million by 2032 with a CAGR of 24.5% during the forecast period 2026-2032.
Published: 2026-07-17
Pages: 109
USD 4250.00 (Single User License)
AI Drug Repurposing Platform - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for AI Drug Repurposing Platform was estimated to be worth US$ 1300 million in 2025 and is projected to reach US$ 6331 million, growing at a CAGR of 24.5% from 2026 to 2032.
Published: 2026-07-17
Pages: 107
USD 3950.00 (Single User License)
Global AI Drug Repurposing Platform Market Research Report 2026
The global AI Drug Repurposing Platform market was valued at US$ 1300 million in 2025 and is anticipated to reach US$ 6331 million by 2032, at a CAGR of 24.5% from 2026 to 2032.
Published: 2026-07-17
Pages: 106
USD 2900.00 (Single User License)